Compare Ascendis Pharma A/S (ASND) vs Wendys Co (WEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Wendys Co — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Wendys Co trades at $7.54 (market cap $1.44B). The key difference: Ascendis Pharma A/S is far larger — about 12.3× Wendys Co's market cap, and Wendys Co pays a 7.41% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WEN | |
|---|---|---|
Market Cap | $17.74B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $11.33 |
52-Week Low | $163.32 | $6.17 |
Enterprise Value | $18.11B | $5.26B |
Dividend Yield | — | 7.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Wendy's (WEN) trades at $7.55, down 0.53% on the day, amid mixed technical signals with a bullish overall trend but neutral oscillators. The stock shows attractive valuation metrics with a P/E of 9.82 and P/S of 0.66, though net income margins have declined from 9.37% in 2023 to 6.77% in 2026. Recent earnings beats and a 7.1% dividend yield provide support, while meme stock volatility and competitive pressures create uncertainty.
The outlook balances value appeal against growth challenges. Positive factors include consistent earnings beats, strong ROE of 120.88%, and analyst consensus price target of $7.96 offering 5.4% upside. Risks include declining profitability, high debt levels (debt-to-asset ratio of 55.68%), and reliance on meme-driven momentum rather than fundamental improvement for recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
